Kalidip “KC” Choudhury, PhD, is the Vice President, Business Development for XBiotech, which is pioneering the discovery and development of targeted antibodies based on its True Human™ technology. He is leading the efforts to commercialize new medicines by advancing its robust pipeline of antibodies derived from natural human immunity. KC previously served as the Vice President, Companion Diagnostics for Definiens, an AstraZeneca company and prior to that as Senior Director for Business Development at Thermo Fisher Scientific in the Immunodiagnostics Division where he was responsible for building and implementing personalized medicine at Thermo Fisher. He has conducted research at Stanford University, Anergen and at Roche Biosciences.